CRLX301

CRLX301 · NewLink Genetics Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CRLX301, covering 2020-06-09 to 2020-06-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]